
Sedatives & hypnotics

Sedatives = "calmative" compounds Hypnotics = compounds causing a condition less or more similar to the physiologic sleep


•often the same; the difference in their action is only in a dose

The sleep in accordance to EEG and other methods: non-REM (non-rapid eye movement) sleep – 70 - 75% REM – the rest; deep sleep which is needed to the organism regeneration (Pre)history•ethanol•bromides (KBr, NaBr)




chloral hydrate


•used as a mild sedative and hypnotic in childern up to now (suppositories)




bromisoval



History Barbiturates $R^1 = R^2 = H$ barbituric acid R^1 , R^2 = alkyl, alkenyl, aryl barbiturates



symetric •slow action onset •mild activity (sedatives) •dlouhé odeznívání long decay of action •usage in analgesic mixtures (irrational, addiction)



asymmetric


•usually more lipophilic

 more efficient, faster onset of action (hypnotics)

•treatment of hyperbilirubinemia and kern icterus in neonates till today (probably irrational)

•used on a mass scale approx. 1912 – 1955
•classification according to duration of action
•up to 50 derivatives
•supress REM-sleep ⇒ the patient is not relaxed

Chemical properties of barbiturates: lactam-lactim tautomerism and salts formed by tautomers




•lactam-lactim tautomerism

dibasic acids

-significant difference of both pK_{a} values \Rightarrow possilbility of monosodium etc. salts well soluble in water

Examples of barbiturates



$$R^{1} = R^{2} = C_{2}H_{5}$$

$$R^{1} = R^{2} = allyl$$


$$R^{1} = C_{6}H_{5}; R^{2} = C_{2}H_{5}$$


barbital allobarbital phenobarbital, syn. luminal

•also antiepileptic, treatment of febrile convulsions in babies, till now in neonates yellow-gum (probably irrational; may be connected with enzyme induction)

•GABA_A receptor agonists

•also in mixtures (Bellaspon[®])






glutethimide

derived from phenobarbitalobsolete sedative and hypnotic

thalidomide


- Contergan[®]
- •originally a hypnotic


withdrawn in 1970th due to tetatogenicity of its S-enantiomer; enantiomers however racemize rapidly; the need of its withdrawal initiated the INN nomenclature introduction
after 2000 used again: imunosuppresant, antineoplastic, angiogenesis inhibitor; the lead compound of a novel group of anticancer drugs Benzodiazepins 1,4-benzodiazepins




R = Hnitrazepam – rather sedativeR = Fflunitrazepam - hypnotic(Rohypnol®)•only minor effect on the REM sleepAE: amnesia, respiration and circulation attenuation•tolerance

"Z-compounds"








(±)-(5R,S): **zopiclon** Zopitin[®] (+)-(5S): **eszopiclon** **zolpidem** Eanox[®], Hypnogen[®]


zaleplon

•also anticonvulsant activity Sonata[®], Zerene[®] ...

GABA_A-receptor – Cl⁻ channel: the target structure for most sedatives and hypnotics and many antiepileptics •alosteric receptor agonists



Melatonine receptor agonists ("melatonergic" drugs) •melatonine is responsible for skin colouring (pigmentation) but also for circadian rhytm •agonists produce the sleep and "reset circadian pacemaker" (="Zeitgeber") to enable it



 administration in the evening \Rightarrow "re-synchronisation" • $T_{1/2}$ too short

•melatonine receptors MT

and MT₂ agonist

tasimelteon syn. BMS-214778 Melatonine receptors

•MT₁ and MT₂

•present in various parts of the brain, important namely in supraschiazmatic nucleus ("circadian pacemaker = Zeitgeber"-SCN)

•G-protein-coupled receptors

•binding of melatonine to $MT_2 \Rightarrow$ "clock resetting"

•binding to $MT_1 \Rightarrow$ suppressing of neuronal firing

•MT, mediated effect of melatonine causes the sleep mainly by means of the "hypothalamic

sleep switch" which under influence of melatonine suppresses neuronal pathes connected with keeping awake and stimulates those connected with the sleep

•thalamus is also of some importance for sleeping effect of melatonine; MT receptors are present here also, spindles which are characterized by non-REM sleep are formed by influence of 5-aminoindole

•there are also other binding structures or sites for melatonine: quinoreductase 2, nuclear receptors which belong into retinoic acid receptors superfamily, Ca²⁺ binding proteins: calmoduline, calreticuline and its analogues in nucleus etc.

Antiepileptics


compounds selectively suppresing CNS used for treatment of epilepsy

Anticonvulsants

•compounds protecting from convulsions used most frequently (but not only) in epilepsy

•many antiepileptics act as anticonvulsants and vice versa but not all

Modes of action of antiepileptics and some of their target structures ${\scriptstyle \bullet GABA_{\tt a}}{\scriptstyle -} receptor$




•voltage gated Na⁺ channels: extending of inactivation decreases the ability of neurons to spread and impulse on higher frequences
•low threshold Ca²⁺ channels: decrease of the flux of Ca²⁺ throuh T type channels leads to decrease of the current of the pacemaker which conditions the thalamic rhytm in peaks and waves which is seen in generalized seizures


Synaptic vesicular protein 2A (SV2A)


•widely spread in whole CNS; its participation in exocytosis of synaptic vesicles and release of neurotransmitters is assumed

•afinity of levetiracetam and its analogues to SV2A closely correlates with their ability to protect against convulsions induced experimentally in animal models

Phenobarbital and its analogues







phenobarbital


Luminal[®] inj., Pheneamal 0.1[®], Phenaemaletten[®] •drug of the 2nd choice: teratogenic, induction of hepatic enzymes, sedation, depression, irritation in childern and the elderly

primidone


Liskantin[®] tbl. •metabolized to phenobarbital •drug of the 2nd choice: sedation, ataxia, attenuated libido

phenytoin 5,5-diphenylhydantoin since 1938 compared with phenobarbital nearly "non-sedative"

acts on Na⁺ channel; prolongs its opened period Epilan D Gerot[®] tbl., Epanutin[®] inj.
in fact monobasic acid; Na⁺ salt also used Isosteric analogues of hydantoins – oxazolidine-2,4-diones a succinimides




dimethadione




ethosuximide Pethinimid[®] cps. •effective in patients with absences but not in generalized and tonic-clonic seizures •does not intertact with other drugs •AE: nausea, vomitting , abdominal pain, headache, alergic rash ...

•block Ca²⁺ type T channels in thalamic neurons

Benzodiazepins 1,4-benzodiazepins






diazepam


•also prevention of febrile convulsions in babies Diazepam Desitin[®]Rectal Tube clonazepam Rivotril[®]tbl., gtt.

 $\bullet \mathsf{GABA}_{\mathsf{A}}\text{-}\mathsf{receptor}$

Dibenzo[*b*,*f*]azepins



carbamazepine-epoxide



valproic acid

Acidum valproicum PhEur

•sodium valproate more fraquently used

Natrii valproas PhEur

•blocks voltage gated Na⁺ channels

•amplifies inhibition effect of GABA


•lowers currents through voltage gated low threshold Ca²⁺-T-channels


•all types of seizures

•teratogenic

Absenor ®, Convulex ® (valproic acid), Depakine ®, Orfiril ® ... (sodium vaproate)

Carbamates





felbamate

•an analogue of meprobamate and carisoprodole

()

Modes of action:

- potentiates GABA mediated inhibition
- blocks voltage gated Na⁺ channels
- blocks ion channels of N-methyl-Daspartate (NMDA) receptors

•treatment of generalized seizures including Lennox–Gastaut syndrome (= a difficult-totreat form of childhood-onset epilepsy characterized by frequent seizures of various types and often accompanied by mental retardation)

•high risk of fatal hepatitis and aplastic anaemia

retigabin


syn. D 23129

developed from the analgesic flupirtine
Modes of action: activates K⁺ channels of
Kv7 type + potentiates GABA-induced
currents in cortical neurones
adjunctive treatment of partial onset
seizures with or without secondary
generalisation in adults aged 18 years and
above

•risk of QT-interval prolongation and psychiatric problems

Trobalt ® authorized by EMA 28th March 2011

Compounds with a sulphonamide eventually a sulphamic acid fragment




topiramate

is not clear

2,3:4,5-Di-*O*-isopropylidene-β-Dfructopyranose sulfamate Topilept[®] tbl., Topilex[®] tbl., Topiragis[®] tbl....

many structural changes proceeded but analogues inactive
blocks Na⁺ channels and high voltage gated Ca²⁺ channels, attenuates effects of excitation transmitters and amplifies GABA effect; impact of carboanhydrase inhibition on its action




sulthiame

a sulphanilamide derivative
introduced 1961
carboanhydrase inhibitor
Ospolot[®]tbl.

zonisamide

- blocks voltage gated Na⁺ channels & Ca²⁺ channels of T type
- inhibits carboanhydrase Zonegran[®]tbl.

Substitution derivatives of γ -amino butyric acid (GABA)



[1-(aminomethyl)cyclohexyl]acetic acid

gabapentin

. . .

Gabagamma[®]tbl., Gabanox[®]tbl.


•AE: weight increase

pregabalin

Lyrica[®] •6 – 8x more effective than gabapentin •also for neuropathic pain and generalized anxious disorder vigabatrin Sabril[®]tbl.

GABA-aminotransferase inhibitor

•bind to $\alpha 2\delta$ subunit of neuronal voltage gated Ca²⁺ channel and inhibit stream of Ca²⁺ •excreted by urine, do not interfere with metabolism of other drugs



tiagabin

Gabitril[®]tbl. •inhibits GABA reuptake in neurones and glias $\Rightarrow \uparrow$ availability of GABA for inbibition of postsynaptic neurones

rufinamide

modulation of Na⁺ channels – keeps their inactive state
AE heart: shortening of QT interval Inovelon[®]tbl.


lamotrigin

Epimil[®]tbl., Lamictal[®]tbl. ... •Na⁺ channels blocker •can also trigger myoclonic

seizures

•embryotoxicity: ↑ risk of cleft of lip and palate

"Geneaology" of racetams




functions enhancers

"non-classical antiepileptics, synaptic vesicular protein 2A (SV2A) antagonists


Antiepileptic racetams

•interact with SV2A

•probably also inhibit high voltage activated (HVA) Ca²⁺ channels (like topiramate)




levetiracetam Keppra[®]



Vomitics

induce vomiting e.g. in intoxicationsan obsolete group




emetine

•alcaloid from the roots of *Cephaëlis ipecacuanha, Rubiaceae*•emetic (central: *medulla oblongata*), antiprotozoal, anthelmintic effects
•formerly also used as "caugh modulator" - combined with codein – Kodynal[®] (50 mg codeine + 5 mg emetine)

Antivomitics (= antiemetics), antikinetics

- parasympatolytics: tropane alkaloids
- •H₁-antihistamines
- •antipsychotics: phenothiazine derivatives
- •compounds enhancing intestinal perislalsis
- •setrons
- •NK-1 antagonists

 $\mathbf{H}_{\!\scriptscriptstyle 1}\text{-}antihistamines$ used as antiemetics and antikinetics



R = H moxastine theoclate

syn. mephenhydrinate

Kinedryl®

R = CH₃ dimenhydrinát

= diphenhydramine + 8-chlorotheophylline

molecular complexes

- motion sickenesses, gravidity nausea
- •AE: sedation


Setrons

•suppress nausea and vomitting by inhibition of serotonine $5-HT_{3}$ receptors on


periphery

•treatment of serious nausea accompanying cancer chemotherapy

•also in general anaesthesia




ondansetrone Emeset[®], Zofran[®] ...



palonosetrone
the most modern
Aloxi[®] inj.

Setrons – derivatives of indole and isosteric heterocycles



tropisetroneffective for 24 hoursfully metabilized in liver

granisetron •isosteric Emegar, Granegis ...

dolasetron

Neurokinine receptor 1 (NK,) antagonists

•substance P (SP) was isolated in 1931, it was purified and its sequence was determined in 1970th : Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂

•belongs to family of small peptides – mammal tachykinins (TK)


•3 types of receptors for TK have been cloned: neurokinines NK₁, NK₂,

NK₃


•SP is predominantly an agonist of NK, receptor

- •1984: administration of SP induced vomitting in dogs
- •1993: resiniferatoxin acts antiemetic in ferrets by competiton with SP
- •1993: the first non-peptide "pure" NK, antagonist permeating through


blood-brain barrier (BBB) was prepared: CP-96,345



Neurokinine receptor 1 (NK $_1$) antagonists




on the mode of application



CP-96,345

Neurokinine receptor 1 (NK $_1$) antagonists



aprepitant

•1st NK₁ antagonist available in clinic Emend[®] cps., Ivemend[®] plv. inf.

casopitant syn. GW679769

•phase 3 of clinical evaluation has been finished

F